GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures

The GIANT study provides real-world evidence of atogepant's effectiveness, safety, and tolerability in patients with HFEM and CM with multiple therapeutic failures and comorbidities. It extends RCT data by showing rapid onset of action, meaningful reductions in pain intensity and interictal disability, high patient satisfaction, and effectiveness even in patients with anti-CGRP mAb failures.

Authors

Institutions

Publication Details

Journal
The Journal of Headache and Pain
Published
2025-05-19
DOI
https://doi.org/10.1186/s10194-025-02068-2
Citations
12
Primary Topic
Migraine and Headache Studies
Type
article
Field-Weighted Citation Impact
17.65

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures

Cinzia Aurilia, Maria Albanese, Piero Barbanti, Rosario Vecchio et al.
12 citations
The Journal of Headache and Pain
Migraine and Headache Studies
17.65
article

GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures

Cinzia Aurilia, Maria Albanese, Piero Barbanti, Rosario Vecchio, Francesca Pistoia, Massimo Autunno, Francesco Bono, Stefano Bonassi, Maurizio Zucco, Antonio Salerno, Paola Torelli, Carlo Tomino, P. Bruno, Fabio Frediani, Cecilia Camarda, Gabriella Egeo, Silvia Strumia, Steno Rinalduzzi, Alberto Doretti, L. Borrello, Giulia Fiorentini, Alice Mannocci, Laura Di Clemente, Stefano Messina, Andrea Galli, Paola Scatena, Angelo Ranieri, Valeria Drago
article en
12 citations

Abstract

The GIANT study provides real-world evidence of atogepant's effectiveness, safety, and tolerability in patients with HFEM and CM with multiple therapeutic failures and comorbidities. It extends RCT data by showing rapid onset of action, meaningful reductions in pain intensity and interictal disability, high patient satisfaction, and effectiveness even in patients with anti-CGRP mAb failures.

The Journal of Headache and PainVol. 26(1)
University of Messina (IT), University of Rome Tor Vergata (IT), University of Parma (IT), Vita-Salute San Raffaele University (IT), University of L'Aquila (IT), Azienda Ospedaliera San Giovanni Addolorata (IT), San Raffaele University of Rome (IT), Accademia di Belle Arti di Frosinone (IT), Ospedale Antonio Cardarelli (IT), Ellis Hospital (US), Ospedale San Carlo (IT), Fatebenefratelli Hospital (IT), Ospedale G.B. Morgagni - L.Pierantoni (IT), IRCCS Ospedale San Raffaele (IT), IRCCS Istituto Auxologico Italiano (IT), Carlo Forlanini Hospital (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Servy Institute for Reproductive Endocrinology (US), Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT), University of Palermo (IT)
Ministero della Salute
Openalex Percentile: Top 1%
Migraine and Headache Studies
17.65
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.